OriCell’s Ori-C101 Advances to Phase II Trial in Liver Cancer
SHANGHAI, China, June 8, 2026 OriCell Therapeutics has achieved a major regulatory and clinical milestone with the National Medical...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
SHANGHAI, China, June 8, 2026 OriCell Therapeutics has achieved a major regulatory and clinical milestone with the National Medical...
SHANGHAI, China, April 10, 2026 Oricell Therapeutics Holdings Limited has successfully closed a $110 million pre-IPO financing round, marking...
